Advanced Proteome Therapeutics (STU:0E81) Total Assets: €0.06 Mil (As of Apr. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Advanced Proteome Therapeutics Total Assets?

Advanced Proteome Therapeutics STU:0E81 Total Assets is €0.06 Mil as of Apr. 2023.

Advanced Proteome Therapeutics's Total Assets for the quarter that ended in Apr. 2023 was €0.06 Mil.

Total Assets is connected with ROA %. Advanced Proteome Therapeutics's annualized ROA % for the quarter that ended in Apr. 2023 was -2,995.56%. Total Assets is also linked to Revenue through Asset Turnover. Advanced Proteome Therapeutics's Asset Turnover for the quarter that ended in Apr. 2023 was 0.00.

Advanced Proteome Therapeutics  (STU:0E81) Total Assets Explanation

Total Assets is connected with ROA %.

Advanced Proteome Therapeutics's annualized ROA % for the quarter that ended in Apr. 2023 is

ROA %=Net Income (Q: Apr. 2023 )/( (Total Assets (Q: Jan. 2023 )+Total Assets (Q: Apr. 2023 ))/ count )
=-5.392/( (0.303+0.057)/ 2 )
=-5.392/0.18
=-2,995.56 %

Note: The Net Income data used here is four times the quarterly (Apr. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Advanced Proteome Therapeutics's Asset Turnover for the quarter that ended in Apr. 2023 is

Asset Turnover
=Revenue (Q: Apr. 2023 )/( (Total Assets (Q: Jan. 2023 )+Total Assets (Q: Apr. 2023 ))/ count )
=0/( (0.303+0.057)/ 2 )
=0/0.18
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Advanced Proteome Therapeutics Total Assets Related Terms

Advanced Proteome Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Advanced Proteome Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics Total Assets Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.15 0.02 0.76 0.63

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 0.63 0.41 0.30 0.06

Advanced Proteome Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Advanced Proteome Therapeutics's Total Assets for the fiscal year that ended in Jul. 2022 is calculated as

Total Assets=Total Equity (A: Jul. 2022 )+Total Liabilities (A: Jul. 2022 )
=-0.837+1.462
=0.63

Advanced Proteome Therapeutics's Total Assets for the quarter that ended in Apr. 2023 is calculated as

Total Assets=Total Equity (Q: Apr. 2023 )+Total Liabilities (Q: Apr. 2023 )
=-0.02+0.077
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of €0.06 Mil mean?
Advanced Proteome Therapeutics (STU:0E81) has a Total Assets of €0.06 Mil as of Apr. 2023. The total amount of assets as recorded on a company's balance sheet. View historical data on Advanced Proteome Therapeutics and its competitors.
Is Advanced Proteome Therapeutics' Total Assets too high?
Advanced Proteome Therapeutics' current Total Assets is €0.06 Mil.
How does Advanced Proteome Therapeutics' Total Assets compare to VRTX and REGN?
Advanced Proteome Therapeutics' Total Assets of €0.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Advanced Proteome Therapeutics and its competitors. Advanced Proteome Therapeutics's current Total Assets is €0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Proteome Therapeutics stock overvalued right now?
Advanced Proteome Therapeutics (STU:0E81) has a current Total Assets of €0.06 Mil. The current Total Assets is €0.06 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Advanced Proteome Therapeutics (STU:0E81), the current Total Assets is €0.06 Mil as of Apr. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Proteome Therapeutics Business Description

Address 104 8337 Eastlake Drive, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.